These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 9658641)
41. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. Navone NM; Labate ME; Troncoso P; Pisters LL; Conti CJ; von Eschenbach AC; Logothetis CJ J Urol; 1999 Jan; 161(1):304-8. PubMed ID: 10037428 [TBL] [Abstract][Full Text] [Related]
42. The p53 tumour suppressor gene and product. Levine AJ Cancer Surv; 1992; 12():59-79. PubMed ID: 1638548 [No Abstract] [Full Text] [Related]
43. p53: from clinical significance to significance in the clinic? Hall AR; Braithwaite A N Z Med J; 1997 Sep; 110(1052):347-8. PubMed ID: 9364174 [No Abstract] [Full Text] [Related]
44. [A protein, molecule of the year 1993]. Bonard EC Rev Med Suisse Romande; 1994 Feb; 114(2):193-4. PubMed ID: 8140378 [No Abstract] [Full Text] [Related]
45. [Study of p53 anti-oncogene in normal and neoplastic cells]. Vojtĕsek B Cas Lek Cesk; 1997 Dec; 136(23):11-3. PubMed ID: 9476369 [No Abstract] [Full Text] [Related]
46. The p53 tumour suppressor gene and human cancer. Roychoudhary G; Mittra I Natl Med J India; 1994; 7(3):106-8. PubMed ID: 8069198 [No Abstract] [Full Text] [Related]
47. [Advances in the research on anti-oncogenes P53]. Li JY; Tong TJ Sheng Li Ke Xue Jin Zhan; 1993 Apr; 24(2):137-8. PubMed ID: 8211064 [No Abstract] [Full Text] [Related]
48. Retinoblastoma and p53 genes as prognostic indicators in urological oncology. Wolff JM; Stephenson RN; Jakse G; Habib FK Urol Int; 1994; 53(1):1-5. PubMed ID: 7974878 [TBL] [Abstract][Full Text] [Related]
49. The limitless role of p53 in cell cycle machinery: good news or bad news? Vogiatzi P; Cassone M; Abbadessa G; Claudio PP Cancer Biol Ther; 2006 Sep; 5(9):1090-3. PubMed ID: 16969127 [TBL] [Abstract][Full Text] [Related]
50. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Heidenberg HB; Bauer JJ; McLeod DG; Moul JW; Srivastava S Urology; 1996 Dec; 48(6):971-9. PubMed ID: 8973691 [No Abstract] [Full Text] [Related]
51. P53 in cancer: a paradigm for modern management of cancer. Steele RJ; Lane DP Surgeon; 2005 Jun; 3(3):197-205. PubMed ID: 16076005 [TBL] [Abstract][Full Text] [Related]
52. The search for prognostic genetic indicators of cancer recurrence. Skuse GR Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):509-10. PubMed ID: 8567356 [No Abstract] [Full Text] [Related]
53. Clinical applications of the p53 tumor suppressor gene. Diamandis EP Clin Chim Acta; 1995 Jun; 237(1-2):79-90. PubMed ID: 7664481 [TBL] [Abstract][Full Text] [Related]
54. The role of the tumour suppressor gene p53. O'Donoghue JM; Kerin MJ; Given HF Eur J Surg Oncol; 1994 Apr; 20(2):175-7. PubMed ID: 8181586 [No Abstract] [Full Text] [Related]
55. p53: a gene for all tumours? Vile RG BMJ; 1993 Nov; 307(6914):1226-7. PubMed ID: 8281051 [No Abstract] [Full Text] [Related]
56. Regulation of p53 function in normal and malignant cells. Tortora V; Bontempo P; Verdicchio M; Armetta I; Abbondanza C; Schiavone EM; Nola E; Puca GA; Molinari AM Adv Exp Med Biol; 1999; 472():89-100. PubMed ID: 10736619 [No Abstract] [Full Text] [Related]
57. "p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999. Maclachlan TK; Meng RD; El-Deiry WS J Cell Physiol; 1999 Nov; 181(2):371-4. PubMed ID: 10497316 [TBL] [Abstract][Full Text] [Related]
58. p53 sweeps through cancer research. Culotta E; Koshland DE Science; 1993 Dec; 262(5142):1958-61. PubMed ID: 7903477 [No Abstract] [Full Text] [Related]
59. Prostate cancer genetics research picks up pace. Reynolds T J Natl Cancer Inst; 1994 Aug; 86(15):1112-5. PubMed ID: 8028032 [No Abstract] [Full Text] [Related]
60. Too much of a good thing? Bode AM Trends Endocrinol Metab; 2002; 13(4):139-40. PubMed ID: 11943553 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]